Acetazolamide for Central Sleep Apnea in Opioid Use Disorder
This study is looking at whether a medication called acetazolamide can help people who have central sleep apnea (CSA) caused by medicines they take for opioid use disorder (MOUD). CSA is a condition where your breathing repeatedly stops and starts during sleep. The study will compare acetazolamide to a placebo (an inactive pill) over 7 days. We want to see if acetazolamide improves your breathing during sleep. You can join if you are between 18 and 100 years old, have CSA while on MOUD, and meet other health requirements. The study aims to enroll 40 participants, but its current status is unclear.
- Study design
- This is an interventional study that will randomize 40 participants to receive either acetazolamide or a placebo.
- What's involved
- You would take either acetazolamide or a placebo daily for 7 days, and have an overnight sleep study at the end of this period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your central apnea index will be measured at 7 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sanjay R Patel, MD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Central Apnea Index (CAI)7 days
The number of central apneas per hour of sleep, assessed by overnight polysomnography. * It can range from 0 to undefined events per hour. * Higher values indicate more severe central sleep apnea.